Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 Plus Bevacizumab in Recurrent Glioblastoma
NCT01648348Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2012
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of carotuximab in glioblastoma multiforme (GBM), sponsored by National Cancer Institute. Started Nov 2012; status: completed.
02
Drugs
carotuximab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01648348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01648348.